News • 21-8-2014
Prof. dr. Freek Verheugt: “Role of aspirin in cancer mortality far from clear”
Prof. dr. F.W.A. Verheugt (Amsterdam) responds to an article in Ann Oncol of this week about the effect of prophylactic aspirin use with regard to cancer and CVD events.
News • 19-8-2014
A more nuanced view from the clinic on the critical BMJ publications about dabigatran
Dr. Michiel Coppens (vascular medicine, Academic Medical Center, Amsterdam, NL) shares his views on the critical publications in BMJ about the safety of using dabigatran.
Relationship between sodium intake and CV diseases more complex than previously thought
18-8-2014 • Mente et al., NEJM 2014
Three studies published in the NEJM examine the relationships between sodium or potassium intake and blood pressure and CV outcomes and find that current recommendations may not be adequate.
News • 11-8-2014
Net benefit for cancer and CVD of long-term aspirin use as primary prevention
Prophylactic aspirin use for at least 5 years at doses between 75 and 325 mg/day seems to have a favourable benefit-harm profile, with regard to cancer and CVD events.
Perceived treatment burden is important factor determining net benefit of lowering HbA1c
7-8-2014 • Vijan S et al., JAMA Intern Med. 2014
If moderate control of HbA1c level (9%) is achieved, a patient’s view of treatment burden is the most important factor determining the net benefit of glucose-lowering treatment.
Visiting a known physician improves outcomes of HF patients after ED discharge
5-8-2014 • Sidhu RS et al., JACC Heart Fail. 2014
Follow-up with a familiar physician was associated with a lower risk of death or hospitalisation, as compared with HF patients who see different or no physicians after treatment and release from ED.
Webcast • Amsterdam
Stroke prevention in atrial fibrillation
Four European Primary Care experts, prof. Richard Hobbs, prof. David Fitzmaurice, Clare Taylor MD and Frans Rutten MD, summarise a fascinating discussion at the stroke prevention in atrial fibrillation expert meeting.
News • 18-8-2014
BMJ criticises safety and use of dabigatran
British Medical Journal writes that information has been withheld about the importance of monitoring plasma levels of dabigatran. We summarise the critic and the producer's response.
News • 13-8-2014
CVD risk in diabetes type 1 does not equal CVD risk in diabetes type 2
AHA and ADA reviewed current insights into differences in pathophysiology between T1DM and T2DM, and call for more research into the mechanism of CVD risk in T1DM.
News • 9-8-2014
AHA/ASA: patients should be informed of link between neck manipulation and cervical dissection
Although a causal relation has not been shown, patients should be informed about the statistical association between cervical manipulative therapy and cervical dissection.
Targeting LDL particle numbers may give better clinical outcome than targeting LDL-c levels
5-8-2014 • Toth et al., Atherosclerosis. 2014
Increases of LDL-P levels are associated with higher risk of CHD events, after accounting for LDL-c levels and patients in whom LDL-P was measured, received more potent statin therapy.
News • 4-8-2014
European approval of apixaban for treatment and prevention of recurrent DVT and PE
The efficacy and safety of apixaban in the treatment of recurrent VTE/VTE-related death had been demonstrated in clinical trials AMPLIFY and AMPLIFY-NXT.
EPCCS Annual meeting 2014
September 18-19, 2014, Brussels, Belgium
All upcoming meetings...
Meeting reports & resources
Report of 6th Annual EPCCS meeting held in London
Report of 5th Annual EPCCS meeting held in Athens
Report of 4th Annual EPCCS meeting held in Berlin
Report of 3rd Annual EPCCS meeting held in Lisbon
All meeting reports...